...
首页> 外文期刊>Frontiers in Public Health >Prospects of Risk-Sharing Agreements for Innovative Therapies in a Context of Deficit Spending in Bulgaria
【24h】

Prospects of Risk-Sharing Agreements for Innovative Therapies in a Context of Deficit Spending in Bulgaria

机译:保加利亚赤字支出背景下创新疗法的风险分担协议的前景

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Innovative therapies are usually defined as newly introduced or modified health technologies with unproven effect or side effect undertaken in the best interest of the patient. These therapies could be situated at any point of the continuum: from genuine innovation with no precedent, to relative innovation representing a small variation from standard therapy, or using a conventional treatment in a different context (1). While the conception of innovative health technologies is not limited by therapeutic form (drugs, devices, procedures) or disease indication, innovative therapies are generally associated with expensive original drugs (2). Inclusion and provision of these therapies tend to be one of the most resource-consuming tasks for national health systems and payers.
机译:创新疗法通常被定义为新引入的或改良的健康技术,其效果或副作用均未根据患者的最大利益进行。这些疗法可以位于连续体的任何位置:从无先例的真正创新到相对于标准疗法的微小差异的相对创新,或在不同背景下使用常规疗法(1)。尽管创新健康技术的概念不受治疗形式(药物,设备,程序)或疾病适应症的限制,但创新疗法通常与昂贵的原始药物有关(2)。包容和提供这些疗法往往是国家卫生系统和付款人最消耗资源的任务之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号